US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALPS Medical Breakthroughs ETF

62.20

-1.5276-2.40%

Post-market: 62.12-0.0806-0.13%19:30 EDT

Volume:19.49K

Turnover:1.21M

Market Cap:225.48M

PE:- -

High:63.39

Open:63.10

Low:61.96

Close:63.73

52wk High:70.85

52wk Low:36.32

Shares:3.63M

Float Shares:3.63M

Volume Ratio:0.41

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

THOMSON REUTERS

Apogee Therapeutics, - Q2 2026 Net Loss $85.90 Mln

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)

Apogee Therapeutics CMO Carl Dambkowski Disposes of USD 737,935 in Common Shares

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

MT Newswires Live

Grail announces FDA advisory committee meeting to review Galleri test PMA

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)

Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

TriSalus Life Sciences Q2 Revenue Beats Estimates

Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26

Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million

Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million

THOMSON REUTERS

Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029

THOMSON REUTERS

Xenon Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/SBIO/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":62.2006,"timestamp":1789761600000,"preClose":63.7282,"halted":0,"volume":19490,"hourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"delay":0,"changeRate":-0.023970549929230697,"floatShares":3625000,"shares":3625000,"eps":0,"marketStatus":"Not Yet Opened","change":-1.5276,"latestTime":"09-18 16:00:00 EDT","open":63.1,"high":63.385,"low":61.96,"amount":1214539.54164,"amplitude":0.022361,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.7282,"sharesOutstanding":2675000,"nav":62.25,"aum":225655960.35,"bidAskSpread":0.002808,"postHourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.4133107687792956,"impliedVol":0.2645,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3625000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4133107687792956,"shares":3625000,"dividePrice":0,"high":63.385,"amplitude":0.022361,"preClose":63.7282,"low":61.96,"week52Low":36.32,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":62.2006,"eps":0,"divideRate":0,"volume":19490,"delay":0,"ttmEps":0,"open":63.1,"prevYearClose":51.22,"prevWeekClose":63.29,"prevMonthClose":66.82,"prevQuarterClose":64.65,"fiveDayClose":63.29,"twentyDayClose":68.56,"sixtyDayClose":60.843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658980067","title":"Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980067?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA10RXHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","LU0053671581.USD","BK4139","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893387","title":"Apogee Therapeutics, - Q2 2026 Net Loss $85.90 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893387?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA10RXHS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE","SBIO","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982377","title":"Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982377?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:40","pubTimestamp":1786354831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","XLV","LU0029874061.USD","XENE","SBIO","LU0128526141.USD","LABU","RLAY","BK4581","HCSG","XBI","BK4139","BK4563","BK4137","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657624586","title":"Apogee Therapeutics CMO Carl Dambkowski Disposes of USD 737,935 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657624586","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657624586?lang=en_us&edition=fundamental","pubTime":"2026-08-08 08:00","pubTimestamp":1786147253,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common sharesApogee Therapeutics Chief Medical Officer Carl Dambkowski sold 5,500 shares on Aug. 5 at USD 134.17.He exercised stock o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260808:nNDL13c7rF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CMO Carl Dambkowski Disposes of USD 737,935 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623471","title":"Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623471?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:00","pubTimestamp":1786129228,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oculis Holding (OCS) and Xenon (XENE) with bullish s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE","OCS","IBRN","BK4007","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628087","title":"Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628087","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628087?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:02","pubTimestamp":1786125732,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals'  recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","BK4139","BK4585","XENE","BK4588","LABU","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642727","title":"Grail announces FDA advisory committee meeting to review Galleri test PMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642727","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642727?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:10","pubTimestamp":1786115445,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","FBT","BK4139","PMA","SBIO","PBE","BK4129","GRAL","BBP","XBIX","IBRN","BBH","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666539","title":"Zentalis Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666539","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666539?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:36","pubTimestamp":1786052164,"startTime":"0","endTime":"0","summary":"Zentalis Q2 net loss widens on higher R&D costsOverviewOncology drug developer's Q2 net loss widened as R&D expenses rose on trial milestonesCompany completed enrollment in DENALI Part 2a and 2b, adva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","ZNTL","ALXO","BK4139","REPL","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657066508","title":"Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066508?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:20","pubTimestamp":1786051212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX), CG Oncology, Inc. (CGON) and Edgewis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inflarx-ifrx-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-inflarx-ifrx-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","CGON","LU0029874061.USD","IE00BGHQF748.EUR","LABU","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","CG","BK4581","IFRX","BK4588","XLV","SBIO","LU0128526141.USD","GPZ","BK4135","XBI","BK4137","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657080663","title":"Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657080663","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657080663?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050101,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings SummaryXenon Pharmaceuticals Inc.XENE.OQreported a quarterly adjusted loss of $1.11 per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SBIO","XENE","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689246","title":"TriSalus Life Sciences Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689246","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657689246?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:32","pubTimestamp":1786048347,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Q2 revenue beats estimatesOverviewOncology device maker's Q2 revenue rose yr/yr, beating analyst expectationsCompany maintained 2026 revenue guidance of $54 mln to $57 mlnOperat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","CGON","BK4139","CHRS","TLSI","BK4535","BK4082","DCTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650667","title":"Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650667","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650667?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:16","pubTimestamp":1786047402,"startTime":"0","endTime":"0","summary":"Biopharma firm IN8bio's Q2 net loss narrows as expenses declineOverviewUS biopharma firm's Q2 net loss narrowed yr/yr, with flat R&D and lower G&A expensesCompany reported updated clinical data showin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SBIO","ALXO","CGON","INAB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0154245756.USD","BK4139","BK4539","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","PSIL","IBRN","IMRX","PRAX","LU2324357040.USD","LU2065171311.SGD","NBIX","LU0154245673.USD","IE00BJT1NW94.SGD","BK4007","LU2065169927.USD","IE0002141913.USD","BK4563","SBIO","LU0109394709.USD","LU0320765992.SGD","GHRS","LU2065171402.SGD","XENE","LU0889565916.HKD","IE00B2B36J28.USD","LU0823416689.USD","IE00BFTCPJ56.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU0314104364.USD","IE00BN0W2W23.USD","BK4585","SG9999014021.USD","BK4588","IBRN","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","NDAQ","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","SBIO","IE00BN0W2V16.EUR","BK4112","BK4139","XENE","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521606","title":"Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521606?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465223","title":"Xenon Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465223?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4YCGCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","IBRN","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763093","title":"CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763093","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763093?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:21","pubTimestamp":1786026089,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. reports results for the quarter ended June 30 - Earnings SummaryCG Oncology, Inc.CGON.OQreported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, lower ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44329Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","CGON","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263440","title":"CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657263440?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:04","pubTimestamp":1786021455,"startTime":"0","endTime":"0","summary":"CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programsCG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% compl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8wxmhj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":112,"code":"91000000","status":"200"}]}}